At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 503 enrolled
Drug / intervention
CD0271 0.3% / CD1579 2.5% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Parallel-group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of CD0271 0.3% / CD1579 2.5% Topical Gel Versus Topical Gel Vehicle in Subjects With Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, and 1 other intervention for Acne Vulgaris. Completed, enrolled 503 participants across 31 sites in 2 countries.
Detailed Summary
The study hypothesis are based on the assumption that : * CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical Gel Vehicle in the overall population and in the subgroup of severe Subjects * CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable safety and tolerability profile
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJul 2013
Primary CompletionMar 2014
TodayJul 2026
First PostedJun 18, 2013
Enrollment StartJul 1, 2013
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.0 years ago
Interventions
CD0271 0.3% / CD1579 2.5%drug
CD0271 0.1% / CD1579 2.5%drug
Topical Gel Vehicledrug